Generalized Pustular Psoriasis (GPP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 

Generalized pustular psoriasis is an uncommon and severe variant of psoriasis, marked by sudden, painful outbreaks of pus-filled blisters covering extensive body areas. It can also bring general symptoms like fever, headaches, extreme fatigue, and skin-burning sensations. Distinguishing it from the more typical plaque psoriasis is essential. Several factors can trigger or worsen generalized pustular psoriasis, including:

  1. Infections: Viral or bacterial infections often exacerbate the condition.
  2. Medications: Corticosteroids are a significant trigger, but other drugs like ciclosporin, terbinafine, and others have been implicated.
  3. Psychological Stress: Stress can lead to deterioration in some individuals.
  4. Hypocalcemia: Low calcium levels, either from the disease or other causes like hypoparathyroidism, can activate the condition.
  5. Pregnancy: Pregnancy is a recognized risk factor.

In certain populations, genetic mutations in IL36RN have been linked to familial and sporadic cases of generalized pustular psoriasis, with specific mutations varying among populations. Diagnostic laboratory tests include elevated erythrocyte sedimentation rate, C-reactive protein levels, lymphopenia followed by leukocytosis, low plasma albumin, zinc, calcium, and abnormal lipid profiles. The disease may be mistaken for a systemic infection due to fever and elevated inflammatory markers during acute phases, potentially leading to incorrect treatment decisions. Without effective treatment, the acute phase can be life-threatening. Prognosis is generally better when there is a clear trigger, such as pregnancy-related generalized pustular psoriasis. However, cases stemming from acrodermatitis continua of Hallopeau tend to have a worse outlook. Treatment for generalized pustular psoriasis involves various approaches - Conservative Treatment includes - Encouraging adequate fluid and protein intake, Monitoring fluid balance, Addressing any concurrent infections with antibiotics, terminating the pregnancy if maternal life is at risk, and preventing hypothermia. Topical Treatment includes- Applying gentle emollients and Using diluted corticosteroids. Systemic Treatment (in order of preference)- First line- Acitretin (not recommended during pregnancy) at a dose of 1 mg/kg/day, Ciclosporin at 3.5 to 5 mg/kg/day, Methotrexate at 0.2 to 0.4 mg/kg/day. Second line- Infliximab, Adalimumab, Etanercept, Prednisolone (only in specific conditions or complications). Third line - Anakinra.

Thelansis’s “Generalized Pustular Psoriasis (GPP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Generalized Pustular Psoriasis (GPP) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Generalized Pustular Psoriasis (GPP) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Generalized Pustular Psoriasis (GPP) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Generalized Pustular Psoriasis (GPP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more